Cite
HARVARD Citation
Miklos, D. et al. (2023). Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study. Journal of clinical oncology. 41 (10), pp. 1876-1887. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Miklos, D. et al. (2023). Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study. Journal of clinical oncology. 41 (10), pp. 1876-1887. [Online].